Journal Article
. 2016 Dec; 18(1):31-41.
doi: 10.1016/S1470-2045(16)30624-6.

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Matthew D Hellmann 1 Naiyer A Rizvi 2 Jonathan W Goldman 3 Scott N Gettinger 4 Hossein Borghaei 5 Julie R Brahmer 6 Neal E Ready 7 David E Gerber 8 Laura Q Chow 9 Rosalyn A Juergens 10 Frances A Shepherd 11 Scott A Laurie 12 William J Geese 13 Shruti Agrawal 13 Tina C Young 13 Xuemei Li 13 Scott J Antonia 14 
  • PMID: 27932067
  •     27 References
  •     340 citations


Background: Nivolumab has shown improved survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. We assessed the safety and activity of combination nivolumab plus ipilimumab as first-line therapy for NSCLC.

Methods: The open-label, phase 1, multicohort study (CheckMate 012) cohorts reported here were enrolled at eight US academic centres. Eligible patients were aged 18 years or older with histologically or cytologically confirmed recurrent stage IIIb or stage IV, chemotherapy-naive NSCLC. Patients were randomly assigned (1:1:1) by an interactive voice response system to receive nivolumab 1 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks, nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 12 weeks, or nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks until disease progression, unacceptable toxicities, or withdrawal of consent. Data from the latter two cohorts, which were considered potentially suitable for further clinical development, are presented in this report; data from the other cohort (as well as several earlier cohorts) are described in the appendix. The primary outcome was safety and tolerability, assessed in all treated patients. This ongoing study is registered with, number NCT01454102.

Findings: Between May 15, 2014, and March 25, 2015, 78 patients were randomly assigned to receive nivolumab every 2 weeks plus ipilimumab every 12 weeks (n=38) or nivolumab every 2 weeks plus ipilimumab every 6 weeks (n=40). One patient in the ipilimumab every-6-weeks cohort was excluded before treatment; therefore 77 patients actually received treatment (38 in the ipilimumab every-12-weeks cohort; 39 in the ipilimumab every-6-weeks cohort). At data cut-off on Jan 7, 2016, 29 (76%) patients in the ipilimumab every-12-weeks cohort and 32 (82%) in the ipilimumab every-6-weeks cohort had discontinued treatment. Grade 3-4 treatment-related adverse events occurred in 14 (37%) patients in the ipilimumab every-12-weeks cohort and 13 (33%) patients in the every-6-weeks cohort; the most commonly reported grade 3 or 4 treatment-related adverse events were increased lipase (three [8%] and no patients), pneumonitis (two [5%] and one [3%] patients), adrenal insufficiency (one [3%] and two [5%] patients), and colitis (one [3%] and two [5%] patients). Treatment-related serious adverse events were reported in 12 (32%) patients in the ipilimumab every-12-weeks cohort and 11 (28%) patients in the every-6-weeks cohort. Treatment-related adverse events (any grade) prompted treatment discontinuation in four (11%) patients in the every-12-weeks cohort and five (13%) patients in the every-6-weeks cohort. No treatment-related deaths occurred. Confirmed objective responses were achieved in 18 (47% [95% CI 31-64]) patients in the ipilimumab every-12-weeks cohort and 15 (38% [95% CI 23-55]) patients in the ipilimumab every-6-weeks cohort; median duration of response was not reached in either cohort, with median follow-up times of 12·8 months (IQR 9·3-15·5) in the ipilimumab every-12-weeks cohort and 11·8 months (6·7-15·9) in the ipilimumab every-6-weeks cohort. In patients with PD-L1 of 1% or greater, confirmed objective responses were achieved in 12 (57%) of 21 patients in the ipilimumab every-12-weeks cohort and 13 (57%) of 23 patients in the ipilimumab every-6-weeks cohort.

Interpretation: In NSCLC, first-line nivolumab plus ipilimumab had a tolerable safety profile and showed encouraging clinical activity characterised by a high response rate and durable response. To our knowledge, the results of this study are the first suggestion of improved benefit compared with anti-PD-1 monotherapy in patients with NSCLC, supporting further assessment of this combination in a phase 3 study.

Funding: Bristol-Myers Squibb.

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, +25 authors, Julie R Brahmer.
N Engl J Med, 2015 Sep 29; 373(17). PMID: 26412456    Free PMC article.
Highly Cited.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.
Therese Phillips, Pauline Simmons, +4 authors, Xiaoling Zhang.
Appl Immunohistochem Mol Morphol, 2015 Sep 01; 23(8). PMID: 26317305    Free PMC article.
Highly Cited.
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Scott N Gettinger, Leora Horn, +26 authors, Julie R Brahmer.
J Clin Oncol, 2015 Apr 22; 33(18). PMID: 25897158    Free PMC article.
Highly Cited.
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
Giorgio Vittorio Scagliotti, Purvish Parikh, +17 authors, David Gandara.
J Clin Oncol, 2008 May 29; 26(21). PMID: 18506025
Highly Cited.
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Luis G Paz-Ares, Filippo de Marinis, +14 authors, Cesare Gridelli.
J Clin Oncol, 2013 Jul 10; 31(23). PMID: 23835707
Highly Cited.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, +21 authors, Timothy A Chan.
Science, 2015 Mar 15; 348(6230). PMID: 25765070    Free PMC article.
Highly Cited.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A Postow, Jason Chesney, +18 authors, F Stephen Hodi.
N Engl J Med, 2015 Apr 22; 372(21). PMID: 25891304    Free PMC article.
Highly Cited.
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Stephen M Ansell, Alexander M Lesokhin, +16 authors, Philippe Armand.
N Engl J Med, 2014 Dec 09; 372(4). PMID: 25482239    Free PMC article.
Highly Cited.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Bernard Escudier, +25 authors, CheckMate 025 Investigators.
N Engl J Med, 2015 Sep 26; 373(19). PMID: 26406148    Free PMC article.
Highly Cited.
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Scott Antonia, Sarah B Goldberg, +8 authors, Naiyer A Rizvi.
Lancet Oncol, 2016 Feb 10; 17(3). PMID: 26858122    Free PMC article.
Highly Cited.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert, Georgina V Long, +25 authors, Paolo A Ascierto.
N Engl J Med, 2014 Nov 18; 372(4). PMID: 25399552
Highly Cited.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, +16 authors, KEYNOTE-024 Investigators.
N Engl J Med, 2016 Oct 11; 375(19). PMID: 27718847
Highly Cited.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
F Stephen Hodi, Jason Chesney, +18 authors, Michael A Postow.
Lancet Oncol, 2016 Sep 14; 17(11). PMID: 27622997    Free PMC article.
Highly Cited.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, +13 authors, J Verweij.
Eur J Cancer, 2008 Dec 23; 45(2). PMID: 19097774
Highly Cited.
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Naiyer A Rizvi, Matthew D Hellmann, +13 authors, Scott Antonia.
J Clin Oncol, 2016 Jun 30; 34(25). PMID: 27354481    Free PMC article.
Highly Cited.
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Jyoti D Patel, Mark A Socinski, +15 authors, Ramaswamy Govindan.
J Clin Oncol, 2013 Oct 23; 31(34). PMID: 24145346    Free PMC article.
Highly Cited.
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
Martin Reck, Joachim von Pawel, +8 authors, Christian Manegold.
J Clin Oncol, 2009 Feb 04; 27(8). PMID: 19188680
Highly Cited.
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Scott Gettinger, Naiyer A Rizvi, +13 authors, Matthew D Hellmann.
J Clin Oncol, 2016 Jun 30; 34(25). PMID: 27354485    Free PMC article.
Highly Cited.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, +22 authors, David R Spigel.
N Engl J Med, 2015 Jun 02; 373(2). PMID: 26028407    Free PMC article.
Highly Cited.
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.
Taku Okazaki, Shunsuke Chikuma, +2 authors, Tasuku Honjo.
Nat Immunol, 2013 Nov 19; 14(12). PMID: 24240160
Highly Cited. Review.
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Scott J Antonia, José A López-Martin, +21 authors, Emiliano Calvo.
Lancet Oncol, 2016 Jun 09; 17(7). PMID: 27269741
Highly Cited.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2015 Jun 02; 373(1). PMID: 26027431    Free PMC article.
Highly Cited.
Genomic landscape of non-small cell lung cancer in smokers and never-smokers.
Ramaswamy Govindan, Li Ding, +18 authors, Richard K Wilson.
Cell, 2012 Sep 18; 150(6). PMID: 22980976    Free PMC article.
Highly Cited.
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Alan Sandler, Robert Gray, +5 authors, David H Johnson.
N Engl J Med, 2006 Dec 15; 355(24). PMID: 17167137
Highly Cited.
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
Jordi Remon, Benjamin Besse, Jean-Charles Soria.
BMC Med, 2017 Mar 14; 15(1). PMID: 28285592    Free PMC article.
Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.
Stefan Langhammer, Joachim Scheerer.
Oncotarget, 2017 Apr 14; 8(26). PMID: 28402937    Free PMC article.
Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.
Marco A J Iafolla, Rosalyn A Juergens.
Front Oncol, 2017 Apr 22; 7. PMID: 28428947    Free PMC article.
The KEY to the end of chemotherapy in non-small cell lung cancer?
Yiqing Huang, Ross A Soo.
Ann Transl Med, 2017 May 10; 5(7). PMID: 28480202    Free PMC article.
Special topics in immunotherapy and radiation therapy: reirradiation and palliation.
Tracey Evans, Christine Ciunci, Lauren Hertan, Daniel Gomez.
Transl Lung Cancer Res, 2017 May 23; 6(2). PMID: 28529895    Free PMC article.
Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?
Chethan Ramamurthy, James L Godwin, Hossein Borghaei.
Curr Treat Options Oncol, 2017 May 24; 18(6). PMID: 28534248
Delivering safer immunotherapies for cancer.
Lauren Milling, Yuan Zhang, Darrell J Irvine.
Adv Drug Deliv Rev, 2017 May 27; 114. PMID: 28545888    Free PMC article.
Highly Cited. Review.
[Prospect and Current Situation of Immune Checkpoint Inhibitors 
in First-line Treatment in Advanced Non-small Cell Lung Cancer Patients].
Haiyang Wang, Xiaoqing Yu, Yun Fan.
Zhongguo Fei Ai Za Zhi, 2017 Jun 24; 20(6). PMID: 28641702    Free PMC article.
PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.
Hans Brunnström, Anna Johansson, +6 authors, Patrick Micke.
Mod Pathol, 2017 Jul 01; 30(10). PMID: 28664936
Highly Cited.
Cancer Immunotherapies: Are They as Effective in the Elderly?
Kate Poropatich, Joel Fontanarosa, +2 authors, Bin Zhang.
Drugs Aging, 2017 Jul 15; 34(8). PMID: 28707274
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.
Cesare Gridelli, Andrea Ardizzoni, +5 authors, Filippo De Marinis.
Transl Lung Cancer Res, 2017 Jul 18; 6(3). PMID: 28713682    Free PMC article.
Atezolizumab for the treatment of non-small cell lung cancer.
Fernando C Santini, Charles M Rudin.
Expert Rev Clin Pharmacol, 2017 Jul 18; 10(9). PMID: 28714780    Free PMC article.
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
Nagashree Seetharamu, Isabel R Preeshagul, Kevin M Sullivan.
Lung Cancer (Auckl), 2017 Aug 02; 8. PMID: 28761384    Free PMC article.
Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma.
Gaurav Bajaj, Manish Gupta, +2 authors, Amit Roy.
J Clin Pharmacol, 2017 Aug 12; 57(12). PMID: 28800166    Free PMC article.
Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future.
Ece Esin.
Biomed Res Int, 2017 Aug 30; 2017. PMID: 28848761    Free PMC article.
From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.
Daphne Day, Arta M Monjazeb, +4 authors, Marcus O Butler.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864726    Free PMC article.
Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.
Christina S Baik, Eric H Rubin, +5 authors, Laura Q M Chow.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864727    Free PMC article.
Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events.
Marianne Davies, Emily A Duffield.
Immunotargets Ther, 2017 Sep 13; 6. PMID: 28894725    Free PMC article.
Predictors of responses to immune checkpoint blockade in advanced melanoma.
N Jacquelot, M P Roberti, +47 authors, L Zitvogel.
Nat Commun, 2017 Sep 21; 8(1). PMID: 28928380    Free PMC article.
Highly Cited.
Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.
John S Yi, Neal Ready, +15 authors, Kent J Weinhold.
Clin Cancer Res, 2017 Sep 28; 23(24). PMID: 28951518    Free PMC article.
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Scott Gettinger, Jungmin Choi, +23 authors, Katerina Politi.
Cancer Discov, 2017 Oct 14; 7(12). PMID: 29025772    Free PMC article.
Highly Cited.
PD-L1 as a biomarker in NSCLC: challenges and future directions.
Matthen Mathew, Rachael A Safyan, Catherine A Shu.
Ann Transl Med, 2017 Oct 24; 5(18). PMID: 29057235    Free PMC article.
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer.
Khinh Ranh Voong, Josephine Feliciano, Daniel Becker, Benjamin Levy.
Ann Transl Med, 2017 Oct 24; 5(18). PMID: 29057236    Free PMC article.
[A Reflection of the New Wave of Immunotherapy on the Clinical Study of 
Chinese Lung Cancer Immunotherapy].
Jingjing Liu, Shuang Zhang, Shuang Li, Ying Cheng.
Zhongguo Fei Ai Za Zhi, 2017 Oct 25; 20(10). PMID: 29061217    Free PMC article.
Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.
Andreas Pircher, Dominik Wolf, +3 authors, Isabel Heidegger.
Int J Mol Sci, 2017 Nov 01; 18(11). PMID: 29088109    Free PMC article.
Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.
Christiane Thallinger, Thorsten Füreder, +9 authors, Christoph Zielinski.
Wien Klin Wochenschr, 2017 Nov 04; 130(3-4). PMID: 29098404    Free PMC article.
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer.
Katerina Ancevski Hunter, Mark A Socinski, Liza C Villaruz.
Mol Diagn Ther, 2017 Nov 10; 22(1). PMID: 29119407    Free PMC article.
Immune checkpoint inhibitors: new strategies to checkmate cancer.
R A M Wilson, T R J Evans, A R Fraser, R J B Nibbs.
Clin Exp Immunol, 2017 Nov 16; 191(2). PMID: 29139554    Free PMC article.
Trial watch: Immune checkpoint blockers for cancer therapy.
Claire Vanpouille-Box, Claire Lhuillier, +10 authors, Lorenzo Galluzzi.
Oncoimmunology, 2017 Nov 18; 6(11). PMID: 29147629    Free PMC article.
Highly Cited. Review.
Biomarkers for immunotherapy in bladder cancer: a moving target.
David H Aggen, Charles G Drake.
J Immunother Cancer, 2017 Nov 22; 5(1). PMID: 29157296    Free PMC article.
PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors.
Yoon Jin Cha, Hyo Sup Shim.
Oncotarget, 2017 Nov 23; 8(52). PMID: 29163763    Free PMC article.
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.
Bingshan Liu, Yongping Song, Delong Liu.
J Hematol Oncol, 2017 Dec 03; 10(1). PMID: 29195503    Free PMC article.
Highly Cited. Review.
Thyroid dysfunctions secondary to cancer immunotherapy.
P Chalan, G Di Dalmazi, +3 authors, P Caturegli.
J Endocrinol Invest, 2017 Dec 15; 41(6). PMID: 29238906    Free PMC article.
Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients.
Oscar Arrieta, Edgar Montes-Servín, +6 authors, Lourdes Barrera.
Oncotarget, 2017 Dec 20; 8(60). PMID: 29254220    Free PMC article.
Recent advances in the management of non-small cell lung cancer.
Samira Shojaee, Patrick Nana-Sinkam.
F1000Res, 2017 Dec 21; 6. PMID: 29259780    Free PMC article.
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
Chee Khoon Lee, Johnathan Man, +7 authors, James Chih-Hsin Yang.
JAMA Oncol, 2017 Dec 23; 4(2). PMID: 29270615    Free PMC article.
Highly Cited. Systematic Review.
Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Chi Young Jung, Scott J Antonia.
Tuberc Respir Dis (Seoul), 2018 Jan 15; 81(1). PMID: 29332322    Free PMC article.
Urgent Need to Define Pretreatment Predictors of Immune Check Point Inhibitors Related Endocrinopathies: A Case Report and Review of Literature.
Vishal Sehgal, Richard Childress.
J Transl Int Med, 2018 Jan 18; 5(4). PMID: 29340281    Free PMC article.
Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy.
Wen Cheng, Dian Fu, Feng Xu, Zhengyu Zhang.
Oncogenesis, 2018 Jan 24; 7(1). PMID: 29358573    Free PMC article.
PD-1/PD-L1 Axis in Lung Cancer.
Fernando C Santini, Matthew D Hellmann.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360723    Free PMC article.
The biology and management of non-small cell lung cancer.
Roy S Herbst, Daniel Morgensztern, Chris Boshoff.
Nature, 2018 Jan 25; 553(7689). PMID: 29364287
Highly Cited. Review.
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
Sandra P D'Angelo, Michelle R Mahoney, +8 authors, Howard Streicher.
Lancet Oncol, 2018 Jan 27; 19(3). PMID: 29370992    Free PMC article.
Highly Cited.
The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
Amy L Cummings, Edward B Garon.
Cancer Biol Med, 2018 Jan 27; 14(4). PMID: 29372100    Free PMC article.
Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).
Irene Moya-Horno, Santiago Viteri, Niki Karachaliou, Rafael Rosell.
Ther Adv Med Oncol, 2018 Feb 01; 10. PMID: 29383034    Free PMC article.
Highly Cited. Review.
Role of immune-checkpoint inhibitors in lung cancer.
Prantesh Jain, Chhavi Jain, Vamsidhar Velcheti.
Ther Adv Respir Dis, 2018 Feb 02; 12. PMID: 29385894    Free PMC article.
Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
Jia-Hung Chen, Kang-Yun Lee, Chaur-Jong Hu, Chen-Chih Chung.
Medicine (Baltimore), 2018 Feb 03; 96(50). PMID: 29390370    Free PMC article.
Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
Izak Faiena, Amy L Cummings, +3 authors, Alexandra Drakaki.
Drug Des Devel Ther, 2018 Feb 09; 12. PMID: 29416316    Free PMC article.
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment.
Jeffrey M Clarke, Daniel J George, Stacey Lisi, April K S Salama.
Target Oncol, 2018 Feb 15; 13(1). PMID: 29441437
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.
Xuexiang Du, Mingyue Liu, +8 authors, Pan Zheng.
Cell Res, 2018 Feb 22; 28(4). PMID: 29463898    Free PMC article.
Highly Cited.
Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report.
Ziwei Guo, Chao Meng, +2 authors, Jun Liang.
Thorac Cancer, 2018 Mar 03; 9(5). PMID: 29498219    Free PMC article.
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients.
Marta Schirripa, Wu Zhang, +18 authors, Heinz-Josef Lenz.
PLoS One, 2018 Mar 10; 13(3). PMID: 29522543    Free PMC article.
Putting the brakes on CTLA-4 inhibition in lung cancer?
Meghan J Mooradian, Justin F Gainor.
Transl Lung Cancer Res, 2018 Mar 14; 7(Suppl 1). PMID: 29531902    Free PMC article.
Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis.
Hao Hu, Qian Zhu, +3 authors, Chang Ying Guo.
Oncotarget, 2018 Mar 17; 9(14). PMID: 29545941    Free PMC article.
Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis.
Junqi Liu, Chuanfeng Zhang, +6 authors, Ruitai Fan.
Oncotarget, 2018 Mar 20; 9(15). PMID: 29552320    Free PMC article.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Nizar M Tannir, +30 authors, CheckMate 214 Investigators.
N Engl J Med, 2018 Mar 22; 378(14). PMID: 29562145    Free PMC article.
Highly Cited.
The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials.
Binghao Zhao, Wenxiong Zhang, +2 authors, Yiping Wei.
Cancer Med, 2018 Mar 25; 7(5). PMID: 29573217    Free PMC article.
Immunotherapy in treatment naïve advanced non-small cell lung cancer.
Vinicius Ernani, Apar Kishor Ganti.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593887    Free PMC article.
Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.
Sandrine Niyongere, Andreas Saltos, Jhanelle E Gray.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593889    Free PMC article.
Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer.
Justin Yeh, Kristen A Marrone, Patrick M Forde.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593890    Free PMC article.
Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer.
Justin F Gainor.
J Thorac Dis, 2018 Mar 31; 10(1). PMID: 29600014    Free PMC article.
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.
Randi B Gombos, Ana Gonzalez, +24 authors, Nicholas S Wilson.
PLoS One, 2018 Apr 05; 13(4). PMID: 29617360    Free PMC article.
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
John M Wrangle, Vamsidhar Velcheti, +26 authors, Mark P Rubinstein.
Lancet Oncol, 2018 Apr 10; 19(5). PMID: 29628312    Free PMC article.
Highly Cited.
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
Roberta Zappasodi, Taha Merghoub, Jedd D Wolchok.
Cancer Cell, 2018 Apr 11; 33(4). PMID: 29634946    Free PMC article.
Highly Cited. Review.
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Tavi Nathanson, +29 authors, Jedd D Wolchok.
Cancer Cell, 2018 Apr 17; 33(5). PMID: 29657128    Free PMC article.
Highly Cited.
Radiotherapy and checkpoint inhibitors: a winning new combination?
Eric C Ko, Silvia C Formenti.
Ther Adv Med Oncol, 2018 Apr 18; 10. PMID: 29662550    Free PMC article.
The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.
Yayi He, Sangtian Liu, +3 authors, Daniel Chan.
Drug Des Devel Ther, 2018 May 08; 12. PMID: 29731605    Free PMC article.
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.
Jaafar Jaafar, Eugenio Fernandez, Heba Alwan, Jacques Philippe.
Endocr Connect, 2018 May 10; 7(5). PMID: 29739808    Free PMC article.
Combination Immunotherapy in Non-small Cell Lung Cancer.
Melina E Marmarelis, Charu Aggarwal.
Curr Oncol Rep, 2018 May 10; 20(7). PMID: 29740718
Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.
Pascale Tomasini, Laurent Greillier, +2 authors, Fabrice Barlesi.
J Thorac Dis, 2018 Jun 01; 10(Suppl 9). PMID: 29850182    Free PMC article.
Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade.
Kerry Reynolds, Molly Thomas, Michael Dougan.
Oncologist, 2018 Jun 02; 23(9). PMID: 29853659    Free PMC article.
Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
Georgios Tsironis, Dimitrios C Ziogas, +4 authors, Meletios-Athanasios Dimopoulos.
Ann Transl Med, 2018 Jun 05; 6(8). PMID: 29862232    Free PMC article.
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
A Lisberg, A Cummings, +23 authors, Edward B Garon.
J Thorac Oncol, 2018 Jun 07; 13(8). PMID: 29874546    Free PMC article.
Highly Cited.
Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer.
Howard J Lee, Jing Zeng, Ramesh Rengan.
Transl Lung Cancer Res, 2018 Jun 08; 7(2). PMID: 29876317    Free PMC article.
Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms.
Megan B Barnet, Wendy A Cooper, Michael J Boyer, Steven Kao.
J Clin Med, 2018 Jun 16; 7(6). PMID: 29904031    Free PMC article.
Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
A Pabani, C A Butts.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910652    Free PMC article.
Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies.
Jiang-Dong Sui, Ying Wang, Yue Wan, Yong-Zhong Wu.
Drug Des Devel Ther, 2018 Jun 21; 12. PMID: 29922039    Free PMC article.
Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
Sonam Puri, Michael Shafique, Jhanelle E Gray.
Curr Treat Options Oncol, 2018 Jun 23; 19(8). PMID: 29931587
Immunotherapy in the Asiatic population: any differences from Caucasian population?
Lunxi Peng, Yi-Long Wu.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951300    Free PMC article.
Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios.
Rebecca Tay, Arsela Prelaj, Raffaele Califano.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951301    Free PMC article.
Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.
Jordi Remon, Laura Mezquita, +2 authors, Noemi Reguart.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951303    Free PMC article.
Oncogene-addicted non-small cell lung cancer and immunotherapy.
Georgios Tsakonas, Simon Ekman.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951305    Free PMC article.
Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors.
Meng Qiao, Tao Jiang, Caicun Zhou.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951304    Free PMC article.
Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients.
Michael Constantin Kirchberger, Alvaro Moreira, +2 authors, Lucie Heinzerling.
Oncotarget, 2018 Jul 11; 9(48). PMID: 29988983    Free PMC article.
Efficacy and immune activation of ipilimumab in early-stage lung cancer patients.
Shingo Noguchi, Kazuhiro Yatera.
J Thorac Dis, 2018 Jul 20; 10(Suppl 17). PMID: 30023087    Free PMC article.
Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma.
Xiao-Yu Chen, Jing Zhang, +6 authors, Jin-Shui Zhu.
Int J Immunopathol Pharmacol, 2018 Jul 27; 32. PMID: 30045644    Free PMC article.
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.
Ugo Testa, Germana Castelli, Elvira Pelosi.
Cancers (Basel), 2018 Aug 01; 10(8). PMID: 30060526    Free PMC article.
Highly Cited. Review.
Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
Venus Sosa Iglesias, Lorena Giuranno, +2 authors, Marc Vooijs.
Front Oncol, 2018 Aug 09; 8. PMID: 30087852    Free PMC article.
Highly Cited. Review.
Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Jingjing Duan, Yu Wang, Shunchang Jiao.
Cancer Med, 2018 Aug 09; 7(9). PMID: 30088347    Free PMC article.
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Yelena Y Janjigian, Johanna Bendell, +13 authors, Dung T Le.
J Clin Oncol, 2018 Aug 16; 36(28). PMID: 30110194    Free PMC article.
Highly Cited.
Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer.
D E Meyers, P M Bryan, S Banerji, D G Morris.
Curr Oncol, 2018 Aug 17; 25(4). PMID: 30111979    Free PMC article.
Design considerations for early-phase clinical trials of immune-oncology agents.
Nolan A Wages, Cody Chiuzan, Katherine S Panageas.
J Immunother Cancer, 2018 Aug 24; 6(1). PMID: 30134959    Free PMC article.
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Hongshu Sui, Ningxia Ma, +4 authors, Jiali Yang.
J Immunol Res, 2018 Aug 31; 2018. PMID: 30159341    Free PMC article.
Highly Cited. Review.
[Research Progress of Immunotherapy for Brain Metastases in Patients 
with Drive Gene Negative NSCLC].
Shuang Zhang, Jingjing Liu, +2 authors, Ying Cheng.
Zhongguo Fei Ai Za Zhi, 2018 Sep 03; 21(8). PMID: 30172268    Free PMC article.
The current state of oligometastatic and oligoprogressive non-small cell lung cancer.
Vasu Tumati, Puneeth Iyengar.
J Thorac Dis, 2018 Sep 13; 10(Suppl 21). PMID: 30206497    Free PMC article.
New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1.
Nicolas Villanueva, Lyudmila Bazhenova.
Ther Adv Respir Dis, 2018 Sep 15; 12. PMID: 30215300    Free PMC article.
Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer.
Shuai Wang, Jiatao Hao, +2 authors, Lijie Tan.
Oncoimmunology, 2018 Sep 18; 7(8). PMID: 30221052    Free PMC article.
Autochthonous murine models for the study of smoker and never-smoker associated lung cancers.
Esra A Akbay, James Kim.
Transl Lung Cancer Res, 2018 Sep 19; 7(4). PMID: 30225211    Free PMC article.
High CCR4 expression in the tumor microenvironment is a poor prognostic indicator in lung adenocarcinoma.
Takahiro Karasaki, Guangliang Qiang, +11 authors, Jun Nakajima.
J Thorac Dis, 2018 Sep 21; 10(8). PMID: 30233846    Free PMC article.
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).
Tara C Mitchell, Omid Hamid, +11 authors, Thomas F Gajewski.
J Clin Oncol, 2018 Sep 29; 36(32). PMID: 30265610    Free PMC article.
Highly Cited.
Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.
Akio Osa, Takeshi Uenami, +30 authors, Atsushi Kumanogoh.
JCI Insight, 2018 Oct 05; 3(19). PMID: 30282824    Free PMC article.
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences.
Xinyu Yan, Shouyue Zhang, +3 authors, Heng Xu.
Front Pharmacol, 2018 Oct 09; 9. PMID: 30294272    Free PMC article.
Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer.
Ewelina Grywalska, Marcin Pasiarski, Stanisław Góźdź, Jacek Roliński.
Onco Targets Ther, 2018 Oct 17; 11. PMID: 30323625    Free PMC article.
Durvalumab in NSCLC: latest evidence and clinical potential.
Nerea Muñoz-Unceta, Isabel Burgueño, Elizabeth Jiménez, Luis Paz-Ares.
Ther Adv Med Oncol, 2018 Oct 23; 10. PMID: 30344651    Free PMC article.
Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation.
Eric C Ko, Kimberly Thomas Benjamin, Silvia C Formenti.
Adv Radiat Oncol, 2018 Oct 30; 3(4). PMID: 30370347    Free PMC article.
TIM-3, a promising target for cancer immunotherapy.
Yayi He, Jie Cao, +3 authors, Fred R Hirsch.
Onco Targets Ther, 2018 Nov 10; 11. PMID: 30410357    Free PMC article.
Highly Cited. Review.
The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis.
Min Peng, Xing Li, +3 authors, Qi Bin Song.
Onco Targets Ther, 2018 Nov 15; 11. PMID: 30425525    Free PMC article.
[Molecular Mechanism of Different Signaling Pathways in Regulating PD-L1 Expression in EGFR Mutated Lung Adenocarcinoma].
Xuefeng Leng, Jiandong Mei, Lunxu Liu.
Zhongguo Fei Ai Za Zhi, 2018 Nov 21; 21(11). PMID: 30454551    Free PMC article.
Spotlight on tumor mutational burden in patients with non-small cell lung carcinoma.
Marius Ilie, Paul Hofman.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505705    Free PMC article.
The clinical utility of tumor mutational burden in non-small cell lung cancer.
Laurent Greillier, Pascale Tomasini, Fabrice Barlesi.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505708    Free PMC article.
Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.
Wenchao Li, Niclas C Blessin, +24 authors, Andrea Hinsch.
BMC Cancer, 2018 Dec 06; 18(1). PMID: 30514251    Free PMC article.
Efficacy and Safety of Ipilimumab plus Chemotherapy for Advanced Lung Cancer: A Systematic Review and Meta-Analysis.
Hongman Zhang, Jie Shen, +3 authors, Jian Zhang.
J Cancer, 2018 Dec 07; 9(23). PMID: 30519362    Free PMC article.
Profiling targetable immune checkpoints in osteosarcoma.
Troy A McEachron, Timothy J Triche, +2 authors, John D Carpten.
Oncoimmunology, 2018 Dec 14; 7(12). PMID: 30524885    Free PMC article.
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
Chien-Chun Steven Pai, John T Huang, +24 authors, Lawrence Fong.
Immunity, 2019 Feb 10; 50(2). PMID: 30737146    Free PMC article.
Highly Cited.
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.
Karthik Suresh, Jarushka Naidoo, +25 authors, Franco D'Alessio.
J Clin Invest, 2019 Jul 17; 129(10). PMID: 31310589    Free PMC article.
Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Yu Chen, Gang Chen, +14 authors, Jian-Ji Pan.
JAMA Netw Open, 2019 Sep 21; 2(9). PMID: 31539077    Free PMC article.
Recent advances and application of PD-1 blockade in sarcoma.
Wenli Zuo, Lingdi Zhao.
Onco Targets Ther, 2019 Nov 07; 12. PMID: 31692518    Free PMC article.
Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Yinghong Zhai, Xiaofei Ye, +4 authors, Jia He.
J Immunother Cancer, 2019 Nov 07; 7(1). PMID: 31694698    Free PMC article.
Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Farastuk Bozorgmehr, Adriane Hommertgen, +9 authors, Stefan Rieken.
BMC Cancer, 2019 Nov 11; 19(1). PMID: 31703637    Free PMC article.
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
Hannah L Buckley, Fiona J Collinson, +15 authors, Naveen S Vasudev.
BMC Cancer, 2019 Nov 16; 19(1). PMID: 31727024    Free PMC article.
KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment.
Amy Lauren Cummings, Kate M Santoso, Jonathan W Goldman.
Transl Lung Cancer Res, 2019 Nov 19; 8(5). PMID: 31737507    Free PMC article.
PD-L1 regulation by SDH5 via β-catenin/ZEB1 signaling.
Zhan Tuo, Yan Zong, +7 authors, Jun Liu.
Oncoimmunology, 2019 Nov 20; 8(12). PMID: 31741753    Free PMC article.
Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis.
Hang Xu, Ping Tan, +5 authors, Qiang Wei.
Front Pharmacol, 2019 Nov 22; 10. PMID: 31749704    Free PMC article.
Systematic Review.
Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis.
Jingli Lu, Lulu Li, +2 authors, Haiyang Meng.
Cancer Med, 2019 Nov 05; 8(18). PMID: 31679184    Free PMC article.
Systematic Review.
New Frontiers for Molecular Pathology.
Joanna Domagala-Kulawik.
Front Med (Lausanne), 2019 Dec 24; 6. PMID: 31867335    Free PMC article.
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.
Min Yuan, Li-Li Huang, +2 authors, Qing Xu.
Signal Transduct Target Ther, 2019 Dec 25; 4. PMID: 31871778    Free PMC article.
Highly Cited. Review.
Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases.
Wang Li, Hong Yu.
J Cancer Res Clin Oncol, 2019 Dec 10; 146(1). PMID: 31813004
Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer.
Cindy Mendes, Jacinta Serpa.
Antioxidants (Basel), 2019 Dec 05; 8(12). PMID: 31795465    Free PMC article.
Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies.
Jingli Lu, Jing Yang, +3 authors, Xiaojian Zhang.
Front Pharmacol, 2020 Jan 11; 10. PMID: 31920646    Free PMC article.
Systematic Review.
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Barbara Melosky, Rosalyn Juergens, +5 authors, Quincy Chu.
Oncologist, 2019 May 30; 25(1). PMID: 31138727    Free PMC article.
Systematic construction and validation of an immune prognostic model for lung adenocarcinoma.
Chenghan Luo, Mengyuan Lei, +7 authors, Yi Zhang.
J Cell Mol Med, 2019 Nov 30; 24(2). PMID: 31779055    Free PMC article.
Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018.
Zhengyang Hu, Ming Li, +3 authors, Qun Wang.
Transl Lung Cancer Res, 2020 Feb 06; 8(6). PMID: 32010587    Free PMC article.
[Alternative treatment options for periorbital basal cell carcinoma].
Vinodh Kakkassery, Steffen Emmert, +7 authors, Ludwig M Heindl.
Ophthalmologe, 2019 Dec 08; 117(2). PMID: 31811367
Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials.
Lijun Da, Yuanjun Teng, +4 authors, Feixue Song.
Front Pharmacol, 2020 Feb 23; 10. PMID: 32082164    Free PMC article.
Systematic Review.
Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors.
Matthew J Bott, Jonathan Cools-Lartigue, +11 authors, Prasad S Adusumilli.
Ann Thorac Surg, 2018 Mar 20; 106(1). PMID: 29550207    Free PMC article.
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.
Amer M Zeidan, Hanna A Knaus, +17 authors, B Douglas Smith.
Clin Cancer Res, 2018 May 03; 24(15). PMID: 29716921    Free PMC article.
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.
Karthik Suresh, Jarushka Naidoo, Cheng Ting Lin, Sonye Danoff.
Chest, 2018 Sep 07; 154(6). PMID: 30189190    Free PMC article.
Highly Cited. Review.
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Daniel Y Wang, Joe-Elie Salem, +24 authors, Douglas B Johnson.
JAMA Oncol, 2018 Sep 23; 4(12). PMID: 30242316    Free PMC article.
Highly Cited. Systematic Review.
Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
Hui Yu, Zhengming Chen, +21 authors, Fred R Hirsch.
J Thorac Oncol, 2018 Sep 27; 14(1). PMID: 30253973    Free PMC article.
Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.
Matthew J Bott, Stephen C Yang, +11 authors, Stephen R Broderick.
J Thorac Cardiovasc Surg, 2019 Feb 06; 158(1). PMID: 30718052    Free PMC article.
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.
Hamzah Abu-Sbeih, Tenglong Tang, +6 authors, Yinghong Wang.
J Immunother Cancer, 2019 Feb 08; 7(1). PMID: 30728076    Free PMC article.
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.
Kellie N Smith, Nicolas J Llosa, +38 authors, Franck Housseau.
J Immunother Cancer, 2019 Feb 13; 7(1). PMID: 30744692    Free PMC article.
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Liliang Xia, Yuanyong Liu, Ying Wang.
Oncologist, 2019 Mar 02; 24(Suppl 1). PMID: 30819829    Free PMC article.
Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma.
Qian Song, Jun Shang, +4 authors, Xianghua Wu.
J Transl Med, 2019 Mar 06; 17(1). PMID: 30832680    Free PMC article.
Highly Cited.
Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies.
Saad Saffo, Tamar H Taddei.
Dig Dis Sci, 2019 Mar 20; 64(4). PMID: 30887150
Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer.
Hyejin Choi, Jiehui Deng, +12 authors, Jedd D Wolchok.
Cell Rep, 2019 Apr 18; 27(3). PMID: 30995478    Free PMC article.
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
Sonja Althammer, Tze Heng Tan, +14 authors, Keith E Steele.
J Immunother Cancer, 2019 May 08; 7(1). PMID: 31060602    Free PMC article.
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Diego Signorelli, Patrizia Giannatempo, +11 authors, Immune-Oncology YOUNG Group.
Biomed Res Int, 2019 Jun 11; 2019. PMID: 31179334    Free PMC article.
Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front.
Maria Saigi, Juan J Alburquerque-Bejar, Montse Sanchez-Cespedes.
Oncogene, 2019 Jun 30; 38(31). PMID: 31253869
Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up.
Anna W Chalmers, Shiven Patel, +6 authors, Wallace Akerley.
Target Oncol, 2019 Jul 28; 14(4). PMID: 31346927
The emergence of neoadjuvant therapy in advanced melanoma.
James Sun, Dennis A Kirichenko, Jonathan S Zager, Zeynep Eroglu.
Melanoma Manag, 2019 Dec 07; 6(3). PMID: 31807278    Free PMC article.
Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer.
Shiqiang Wang, Chongling Hu, Fei Xie, Yanhui Liu.
Onco Targets Ther, 2020 Mar 12; 13. PMID: 32158220    Free PMC article.
Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies.
Sonam Puri, Michael Shafique.
Drugs Context, 2020 Mar 12; 9. PMID: 32158484    Free PMC article.
[Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer].
Hanfei Guo, Rilan Bai, Jiuwei Cui.
Zhongguo Fei Ai Za Zhi, 2020 Feb 26; 23(2). PMID: 32093454    Free PMC article.
Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma.
Jason Adhikaree, Julia Moreno-Vicente, +2 authors, Poulam M Patel.
Cells, 2020 Jan 25; 9(2). PMID: 31973059    Free PMC article.
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Manuela Tiako Meyo, Anne Jouinot, +16 authors, Benoit Blanchet.
Cancers (Basel), 2020 Feb 23; 12(2). PMID: 32085544    Free PMC article.
Determinants of Resistance to Checkpoint Inhibitors.
Linda Tran, Dan Theodorescu.
Int J Mol Sci, 2020 Mar 01; 21(5). PMID: 32111080    Free PMC article.
Immune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?
Caterina Vivaldi, Silvia Catanese, +7 authors, Lorenzo Fornaro.
Int J Mol Sci, 2020 Mar 04; 21(5). PMID: 32121290    Free PMC article.
Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer.
Chennianci Zhu, Weihao Zhuang, +2 authors, Wen-Bin Ou.
Transl Lung Cancer Res, 2020 Mar 25; 9(1). PMID: 32206559    Free PMC article.
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Neal Ready, Matthew D Hellmann, +25 authors, Suresh S Ramalingam.
J Clin Oncol, 2019 Feb 21; 37(12). PMID: 30785829    Free PMC article.
Highly Cited.
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.
Steve Lu, Julie E Stein, +11 authors, Janis M Taube.
JAMA Oncol, 2019 Jul 19; 5(8). PMID: 31318407    Free PMC article.
Highly Cited.
Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma.
Sarah Harris-Bookman, Dimitrios Mathios, +18 authors, Michael Lim.
Int J Cancer, 2018 Sep 25; 143(12). PMID: 30248181    Free PMC article.
Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis.
Robin Park, Laercio Lopes, +2 authors, Anwaar Saeed.
Front Oncol, 2020 Apr 08; 10. PMID: 32257944    Free PMC article.
Systematic Review.
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept.
Thierry Berghmans, Valérie Durieux, Lizza E L Hendriks, Anne-Marie Dingemans.
Front Med (Lausanne), 2020 Apr 09; 7. PMID: 32266275    Free PMC article.
Systematic Review.
Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Marine Leclerc, Laura Mezquita, +4 authors, Fathia Mami-Chouaib.
Front Immunol, 2019 Jul 25; 10. PMID: 31333652    Free PMC article.
Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging.
Adam J Grippin, Brandon Wummer, +12 authors, Duane A Mitchell.
ACS Nano, 2019 Nov 16; 13(12). PMID: 31730332    Free PMC article.
Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens.
Huihong Xu, Laura Bratton, +2 authors, Zhongren Zhou.
Cytojournal, 2019 Jan 22; 15. PMID: 30662515    Free PMC article.
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Matthew D Hellmann, Tudor-Eliade Ciuleanu, +21 authors, Luis Paz-Ares.
N Engl J Med, 2018 Apr 17; 378(22). PMID: 29658845    Free PMC article.
Highly Cited.
Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer.
Liangliang Cai, Hua Bai, +13 authors, Jie Wang.
J Immunother Cancer, 2019 Jul 28; 7(1). PMID: 31349879    Free PMC article.
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study.
Suneel D Kamath, Aparna Kalyan, +4 authors, Mary Mulcahy.
Oncologist, 2019 Nov 20; 25(5). PMID: 31740568    Free PMC article.
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.
Sandip P Patel, Megan Othus, +19 authors, Razelle Kurzrock.
Clin Cancer Res, 2020 Jan 24; 26(10). PMID: 31969335    Free PMC article.
Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer.
Pengfei Cui, Di Huang, +9 authors, Yi Hu.
Ther Adv Med Oncol, 2020 May 20; 12. PMID: 32426052    Free PMC article.
Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy.
Filippo Galli, Jesus Vera Aguilera, +3 authors, Alberto Signore.
J Exp Clin Cancer Res, 2020 May 20; 39(1). PMID: 32423420    Free PMC article.
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yunfang Yu, Dongqiang Zeng, +8 authors, Herui Yao.
JAMA Netw Open, 2019 Jul 11; 2(7). PMID: 31290993    Free PMC article.
Highly Cited.
Beyond the Variants: Mutational Patterns in Next-Generation Sequencing Data for Cancer Precision Medicine.
Megan Parilla, Lauren L Ritterhouse.
Front Cell Dev Biol, 2020 Jun 09; 8. PMID: 32509788    Free PMC article.
Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
Susumu Suzuki, Tetsuya Ogawa, +7 authors, Toyonori Tsuzuki.
Cancer Sci, 2020 Apr 19; 111(6). PMID: 32304268    Free PMC article.
Non-Small Cell Lung Cancer Patient Preferences for First-Line Treatment: A Discrete Choice Experiment.
Joanna P MacEwan, Komal Gupte-Singh, Lauren M Zhao, Karen L Reckamp.
MDM Policy Pract, 2020 Jun 18; 5(1). PMID: 32548305    Free PMC article.
Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench.
Rui Jin, Jing Zhao, +4 authors, Yang Xia.
Ther Adv Med Oncol, 2020 Jun 23; 12. PMID: 32565926    Free PMC article.
Primary Adrenal Insufficiency during Immune Checkpoint Inhibitor Treatment: Case Reports and Review of the Literature.
Carlos Salinas, Alex Renner, +2 authors, Mauricio Burotto.
Case Rep Oncol, 2020 Jul 01; 13(2). PMID: 32595473    Free PMC article.
Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy.
Lukas Käsmann, Chukwuka Eze, +6 authors, Farkhad Manapov.
Radiat Oncol, 2020 Jul 11; 15(1). PMID: 32646443    Free PMC article.
Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer.
Stefanie Schatz, Markus Falk, +12 authors, Lukas C Heukamp.
Cancers (Basel), 2020 Jul 01; 12(6). PMID: 32599951    Free PMC article.
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
Eileen M O'Reilly, Do-Youn Oh, +11 authors, Philip Agop Philip.
JAMA Oncol, 2019 Jul 19; 5(10). PMID: 31318392    Free PMC article.
Highly Cited.
Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
J Nicholas Bodor, Yanis Boumber, Hossein Borghaei.
Cancer, 2019 Nov 07; 126(2). PMID: 31691957    Free PMC article.
Identification and validation of tumor microenvironment-related genes of prognostic value in lung adenocarcinoma.
Jingyan Yuan, Bo Yuan, +7 authors, Shuanying Yang.
Oncol Lett, 2020 Jul 30; 20(2). PMID: 32724420    Free PMC article.
Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis.
Bi-Cheng Wang, Peng-Cheng Li, +2 authors, Quentin Liu.
Medicine (Baltimore), 2020 Jul 16; 99(28). PMID: 32664183    Free PMC article.
Systematic Review.
Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD-1/PD-L1 agents?
Michal Sternschuss, Nir Peled, +6 authors, Alona Zer.
Thorac Cancer, 2020 Jun 18; 11(8). PMID: 32548905    Free PMC article.
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
Ila Datar, Miguel F Sanmamed, +22 authors, Kurt A Schalper.
Clin Cancer Res, 2019 May 06; 25(15). PMID: 31053602    Free PMC article.
Highly Cited.
A Prognostic Nomogram Combining Immune-Related Gene Signature and Clinical Factors Predicts Survival in Patients With Lung Adenocarcinoma.
Congkuan Song, Zixin Guo, +4 authors, Weidong Hu.
Front Oncol, 2020 Aug 28; 10. PMID: 32850406    Free PMC article.
Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
Farastuk Bozorgmehr, Inn Chung, +6 authors, Stefan Rieken.
BMC Cancer, 2020 Aug 28; 20(1). PMID: 32842974    Free PMC article.
Rational design of anti-GITR-based combination immunotherapy.
Roberta Zappasodi, Cynthia Sirard, +16 authors, Taha Merghoub.
Nat Med, 2019 May 01; 25(5). PMID: 31036879    Free PMC article.
Highly Cited.
[Advances of the Correlation between Driver Gene Status and Immunotherapy 
in Non-small Cell Lung Cancer].
Jie Chen, Da Jiang, Fang Huang.
Zhongguo Fei Ai Za Zhi, 2019 Apr 25; 22(4). PMID: 31014442    Free PMC article.
Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Xuefeng Bai, Xiahong Lin, +4 authors, Yong Zhuang.
Endocrine, 2020 Jun 09; 69(3). PMID: 32507965    Free PMC article.
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
Ana Bocanegra, Ester Blanco, +7 authors, Grazyna Kochan.
Int J Mol Sci, 2020 Aug 23; 21(16). PMID: 32824655    Free PMC article.
[First-line Combination Immunotherapy in Advanced Non-small Cell Lung Cancer].
Xiaoxiao Peng, Qing Zhou.
Zhongguo Fei Ai Za Zhi, 2018 Dec 29; 21(12). PMID: 30591101    Free PMC article.
The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.
Xiaoyang Zhai, Jian Zhang, +4 authors, Hui Zhu.
Cancer Biol Med, 2020 Sep 19; 17(3). PMID: 32944393    Free PMC article.
Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.
Jiaqi Liang, Ming Li, +7 authors, Lijie Tan.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953506    Free PMC article.
Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell?
Mariam Alexander, Jose Galeas, Haiying Cheng.
J Thorac Dis, 2019 Jan 12; 10(Suppl 33). PMID: 30631537    Free PMC article.
Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis.
Chang-Ying Guo, Si-Cong Jiang, Yu-Kang Kuang, Hao Hu.
J Cancer, 2019 Jan 22; 10(1). PMID: 30662532    Free PMC article.
Macrophage Origin, Metabolic Reprogramming and IL-1 Signaling: Promises and Pitfalls in Lung Cancer.
Emma Guilbaud, Emmanuel L Gautier, Laurent Yvan-Charvet.
Cancers (Basel), 2019 Mar 06; 11(3). PMID: 30832375    Free PMC article.
Making cold malignant pleural effusions hot: driving novel immunotherapies.
Pranav Murthy, Chigozirim N Ekeke, +6 authors, Michael T Lotze.
Oncoimmunology, 2019 Mar 25; 8(4). PMID: 30906651    Free PMC article.
A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer.
Jose M Pacheco, D Ross Camidge, Robert C Doebele, Erin Schenk.
Front Oncol, 2019 Apr 16; 9. PMID: 30984621    Free PMC article.
Highly Cited. Review.
Immuno-checkpoint inhibitors in metastatic esophago-gastric cancer.
Marina Schena, Angelo F Battaglia, Antonio Trogu.
J Thorac Dis, 2019 Apr 19; 11(Suppl 3). PMID: 30997225    Free PMC article.
Extensive exploration of T cell heterogeneity in cancers by single cell sequencing.
Xiaofang Wang, Yangqiu Li.
Chin J Cancer Res, 2019 Jun 04; 31(2). PMID: 31156311    Free PMC article.
Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date.
Jordi Remon, Laura Esteller, Álvaro Taus.
Cancer Manag Res, 2019 Jun 20; 11. PMID: 31213908    Free PMC article.
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer.
Frank Weinberg, Shirish Gadgeel.
Lung Cancer (Auckl), 2019 Jun 27; 10. PMID: 31239797    Free PMC article.
A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer.
Ning Wan, Bo Ji, +4 authors, Wenjie Huang.
Onco Targets Ther, 2019 Jul 16; 12. PMID: 31303759    Free PMC article.
Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events.
Kenji Ihara.
Clin Pediatr Endocrinol, 2019 Aug 07; 28(3). PMID: 31384097    Free PMC article.
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer.
Zhenbin Qiu, Zihao Chen, Chao Zhang, Wenzhao Zhong.
Exp Hematol Oncol, 2019 Aug 30; 8. PMID: 31463163    Free PMC article.
The role and therapeutic implications of T cells in cancer of the lung.
Samuel C Neeve, Bruce Ws Robinson, Vanessa S Fear.
Clin Transl Immunology, 2019 Sep 06; 8(8). PMID: 31485330    Free PMC article.
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.
Jia Li Low, Robert J Walsh, +2 authors, Ross A Soo.
Ther Adv Med Oncol, 2019 Sep 10; 11. PMID: 31497071    Free PMC article.
Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings.
Tsutomu Nishida, Hideki Iijima, Shiro Adachi.
World J Gastrointest Pathophysiol, 2019 Sep 29; 10(2). PMID: 31559106    Free PMC article.
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy.
Leilei Ai, Jian Chen, +4 authors, Xiaochun Yang.
Drug Des Devel Ther, 2020 Sep 29; 14. PMID: 32982171    Free PMC article.
Prognostic value of immune related genes in lung adenocarcinoma.
Han Wang, Meng-Sen Wang, +4 authors, Wen-Jie Wang.
Oncol Lett, 2020 Sep 30; 20(5). PMID: 32989393    Free PMC article.
The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives.
Danilo Rocco, Luigi D Gravara, Cesare Gridelli.
Curr Clin Pharmacol, 2019 Aug 11; 15(1). PMID: 31400270    Free PMC article.
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer.
Huabin Hu, Longjiang She, +7 authors, Jin Huang.
Front Oncol, 2020 Oct 06; 10. PMID: 33014826    Free PMC article.
Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Pancheng Wu, Yi Zheng, +2 authors, Naixin Liang.
J Transl Med, 2020 Oct 09; 18(1). PMID: 33028329    Free PMC article.
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Thomas Yau, Yoon-Koo Kang, +18 authors, Chiun Hsu.
JAMA Oncol, 2020 Oct 02; 6(11). PMID: 33001135    Free PMC article.
Immune checkpoint inhibitor-related dermatologic adverse events.
Amaris N Geisler, Gregory S Phillips, +5 authors, Mario E Lacouture.
J Am Acad Dermatol, 2020 May 27; 83(5). PMID: 32454097    Free PMC article.
Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study.
Jian-Nan Liu, Xiang-Shuo Kong, +3 authors, Qi-Feng Chen.
Front Immunol, 2020 Oct 20; 11. PMID: 33072070    Free PMC article.
Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer.
Chaoyue Su, Hui Wang, +7 authors, Jianye Zhang.
Front Oncol, 2020 Oct 20; 10. PMID: 33072580    Free PMC article.
Identification of a Novel Tumor Microenvironment-Associated Eight-Gene Signature for Prognosis Prediction in Lung Adenocarcinoma.
Chao Ma, Huan Luo, +4 authors, Zongqiang Fu.
Front Mol Biosci, 2020 Oct 27; 7. PMID: 33102522    Free PMC article.
Lung cancer treatment in the era of immunotherapy.
Yang Xu, Liang-An Chen.
Chin Med J (Engl), 2020 Sep 25; 133(20). PMID: 32969863    Free PMC article.
The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis.
Mingkai Li, Linlin Huang, +7 authors, Fuli Mi.
Medicine (Baltimore), 2020 Oct 22; 99(42). PMID: 33080690    Free PMC article.
Systematic Review.
From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy.
Andrea Sesma, Julián Pardo, +12 authors, Rodrigo Lastra.
Cancers (Basel), 2020 Oct 18; 12(10). PMID: 33066479    Free PMC article.
When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report.
Dimitrios C Ziogas, Aikaterini Gkoufa, +4 authors, Helen Gogas.
J Immunother Cancer, 2020 Nov 05; 8(2). PMID: 33144335    Free PMC article.
The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
K Bishay, P Tandon, +2 authors, J D McCurdy.
Curr Oncol, 2020 Nov 12; 27(5). PMID: 33173388    Free PMC article.
Systematic Review.
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.
Filippo G Dall'Olio, Francesca Abbati, +7 authors, Andrea Ardizzoni.
Ther Adv Med Oncol, 2020 Nov 17; 12. PMID: 33193825    Free PMC article.
FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression.
Pamela Abdayem, David Planchard.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209637    Free PMC article.
Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
Roberta Zappasodi, Sadna Budhu, +13 authors, Jedd D Wolchok.
Cancer Cell, 2018 Jun 13; 33(6). PMID: 29894689    Free PMC article.
Highly Cited.
The lung microenvironment: an important regulator of tumour growth and metastasis.
Nasser K Altorki, Geoffrey J Markowitz, +5 authors, Vivek Mittal.
Nat Rev Cancer, 2018 Dec 12; 19(1). PMID: 30532012    Free PMC article.
Highly Cited. Review.
Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Shinji Miwa, Norio Yamamoto, +3 authors, Hiroyuki Tsuchiya.
Int J Mol Sci, 2019 Jan 10; 20(1). PMID: 30621224    Free PMC article.
Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma.
Margaret Ottaviano, Sabino De Placido, Paolo Antonio Ascierto.
Virchows Arch, 2019 Feb 13; 474(4). PMID: 30747264
A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).
Nadja M Meindl-Beinker, Johannes Betge, +7 authors, Nicolai Haertel.
BMC Cancer, 2019 Mar 16; 19(1). PMID: 30871493    Free PMC article.
Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases.
Yanina J L Jansen, Gontran Verset, +5 authors, Bart Neyns.
ESMO Open, 2019 Apr 10; 4(2). PMID: 30962963    Free PMC article.
PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
Yanhui Chen, Quanxing Liu, +8 authors, Henghui Zhang.
J Exp Clin Cancer Res, 2019 May 16; 38(1). PMID: 31088500    Free PMC article.
Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.
Silvia Martina Ferrari, Poupak Fallahi, +8 authors, Alessandro Antonelli.
Int J Mol Sci, 2019 May 30; 20(10). PMID: 31137683    Free PMC article.
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis.
Lihu Gu, Parikshit Asutosh Khadaroo, +8 authors, Manman Chen.
BMC Cancer, 2019 Jun 12; 19(1). PMID: 31182049    Free PMC article.
Systematic Review.
Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Xiaoying Sun, Raheleh Roudi, +9 authors, Xin Li.
BMC Cancer, 2019 Jun 12; 19(1). PMID: 31182061    Free PMC article.
Systematic Review.
Combination of CTLA-4 and PD-1 blockers for treatment of cancer.
Anand Rotte.
J Exp Clin Cancer Res, 2019 Jun 15; 38(1). PMID: 31196207    Free PMC article.
Highly Cited. Review.
Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer.
Wentao Tian, Chenghui Cao, Long Shu, Fang Wu.
Onco Targets Ther, 2020 Dec 03; 13. PMID: 33262610    Free PMC article.

;. PMID: 33323935
ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer.
Liangliang Cai, Jianchun Duan, +8 authors, Jie Wang.
Front Immunol, 2020 Dec 17; 11. PMID: 33324391    Free PMC article.
Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy.
Muhammad Khan, Zhihong Zhao, +2 authors, Guixiang Liao.
Front Immunol, 2020 Dec 18; 11. PMID: 33329567    Free PMC article.
Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis.
Sibo Tian, Jeffrey M Switchenko, +9 authors, Kristin A Higgins.
Int J Radiat Oncol Biol Phys, 2020 Jan 27; 108(1). PMID: 31982496    Free PMC article.
Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.
Yuxin Sun, Chi Shao, +6 authors, Zuojun Xu.
Asia Pac J Clin Oncol, 2020 Aug 07; 16(6). PMID: 32757454    Free PMC article.
Characterizing heterogeneity of non-small cell lung tumour microenvironment to identify signature prognostic genes.
Kai Mi, Fuhui Chen, +8 authors, Desi Shang.
J Cell Mol Med, 2020 Nov 14; 24(24). PMID: 33184998    Free PMC article.
Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors.
Leilei Wu, Linping Ke, +2 authors, Xue Meng.
Front Oncol, 2021 Jan 05; 10. PMID: 33392095    Free PMC article.
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.
Benjamin C Creelan, Tammie C Yeh, +11 authors, Don L Gibbons.
Br J Cancer, 2020 Oct 06; 124(2). PMID: 33012782    Free PMC article.
Targeting metastatic cancer.
Karuna Ganesh, Joan Massagué.
Nat Med, 2021 Jan 15; 27(1). PMID: 33442008    Free PMC article.
Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.
Hanna R Kemeny, Aladine A Elsamadicy, +15 authors, Peter E Fecci.
Clin Cancer Res, 2019 Nov 21; 26(5). PMID: 31744830    Free PMC article.
Identification of Four Genes as Prognosis Signatures in Lung Adenocarcinoma Microenvironment.
Yan Yao, Tingting Zhang, +4 authors, Changgang Sun.
Pharmgenomics Pers Med, 2021 Jan 16; 14. PMID: 33447073    Free PMC article.
A novel immunogenomic prognostic signature in lung squamous carcinoma.
Jili Hou, Qiuying Zhong.
Medicine (Baltimore), 2021 Jan 21; 100(2). PMID: 33466167    Free PMC article.
Immunotherapy response modeling by ex-vivo organ culture for lung cancer.
Iris Kamer, Elizabeta Bab-Dinitz, +8 authors, Jair Bar.
Cancer Immunol Immunother, 2021 Jan 24; 70(8). PMID: 33484295
Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy.
Marsha Pellegrino, Francesca Del Bufalo, +3 authors, Emmanuel de Billy.
Cells, 2020 Dec 31; 10(1). PMID: 33374128    Free PMC article.
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434).
Toshihiko Doi, Yutaka Fujiwara, +12 authors, Noboru Yamamoto.
Invest New Drugs, 2020 Jun 22; 39(1). PMID: 32564277
Immune cell infiltration features and related marker genes in lung cancer based on single-cell RNA-seq.
R Zhong, D Chen, +3 authors, H Zhong.
Clin Transl Oncol, 2020 Jul 14; 23(2). PMID: 32656582
The cutting-edge progress of immune-checkpoint blockade in lung cancer.
Fei Zhou, Meng Qiao, Caicun Zhou.
Cell Mol Immunol, 2020 Nov 13; 18(2). PMID: 33177696    Free PMC article.
Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer.
Caroline Huynh, Logan A Walsh, Jonathan D Spicer.
Transl Lung Cancer Res, 2021 Feb 12; 10(1). PMID: 33569337    Free PMC article.
A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma.
Congkuan Song, Zhiquan Wu, +4 authors, Weidong Hu.
Front Cell Dev Biol, 2021 Feb 16; 9. PMID: 33585490    Free PMC article.
Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution Experience.
Stefania Nobili, Daniele Lavacchi, +8 authors, Enrico Mini.
Oncol Res, 2019 Dec 07; 28(3). PMID: 31806078    Free PMC article.
Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors.
Thomas Kelleher, Junliang Cai, Nicholas Aj Botwood, Dominic F Labriola.
J Immunother Cancer, 2021 Feb 10; 9(2). PMID: 33558277    Free PMC article.
Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies.
Shirley Xu, Umesh C Sharma, Cheyanna Tuttle, Saraswati Pokharel.
Front Cardiovasc Med, 2021 Feb 23; 8. PMID: 33614750    Free PMC article.
Making the Most of Complexity to Create Opportunities: Comprehensive Genomic Profiling and Molecular Tumor Board for Patients with Non-Small Cell Lung Cancer (NSCLC).
Caterina Fumagalli, Elena Guerini-Rocco, Massimo Barberis.
Cancers (Basel), 2021 Feb 10; 13(4). PMID: 33557047    Free PMC article.
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.
Jingjing Qu, Quanhui Mei, +4 authors, Jianying Zhou.
Ther Adv Med Oncol, 2021 Mar 02; 13. PMID: 33643442    Free PMC article.
Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
Yuqian Feng, Huimin Jin, +5 authors, Shanming Ruan.
Front Pharmacol, 2021 Mar 16; 12. PMID: 33716732    Free PMC article.
Delivery of gefitinib with an immunostimulatory nanocarrier improves therapeutic efficacy in lung cancer.
Dingwei Diao, Jianxue Zhai, +7 authors, Kaican Cai.
Transl Lung Cancer Res, 2021 Mar 16; 10(2). PMID: 33718033    Free PMC article.
A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.
Yunes Panahi, Amir Hossein Mohammadzadeh, +3 authors, Amirhossein Sahebkar.
Adv Exp Med Biol, 2021 Mar 17; 1286. PMID: 33725344
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.
Philippe Armand, Alexander Lesokhin, +5 authors, Stephen M Ansell.
Leukemia, 2020 Jul 01; 35(3). PMID: 32601377    Free PMC article.
PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
David J Pinato, Alessio Cortellini, +14 authors, Rohini Sharma.
BMC Cancer, 2021 Mar 25; 21(1). PMID: 33757459    Free PMC article.
Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab.
Amirali Karimi, Sanam Alilou, Hamid Reza Mirzaei.
Front Oncol, 2021 Mar 27; 11. PMID: 33767992    Free PMC article.
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression.
Arsela Prelaj, Chiara Carlotta Pircher, +12 authors, Sara Elena Rebuzzi.
Cancers (Basel), 2021 Apr 04; 13(6). PMID: 33803958    Free PMC article.
Agonistic CD40 Antibodies in Cancer Treatment.
Dijana Djureinovic, Meina Wang, Harriet M Kluger.
Cancers (Basel), 2021 Apr 04; 13(6). PMID: 33804039    Free PMC article.
Baseline Hedgehog Pathway Activation and Increase of Plasma Wnt1 Protein Are Associated with Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer.
Camille Mehlman, Paul Takam Kamga, +8 authors, Etienne Giroux Leprieur.
Cancers (Basel), 2021 Apr 04; 13(5). PMID: 33807552    Free PMC article.
Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution.
R Kleef, R Nagy, +7 authors, T Bakacs.
Cancer Immunol Immunother, 2020 Nov 06; 70(5). PMID: 33151369    Free PMC article.
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
Taofeek K Owonikoko, Keunchil Park, +22 authors, Hye Ryun Kim.
J Clin Oncol, 2021 Mar 09; 39(12). PMID: 33683919    Free PMC article.
[LIM-domain binding protein 2 regulated by m6A modification inhibits lung adenocarcinoma cell proliferation in vitro].
D Zhai, G Wang, +3 authors, J Yin.
Nan Fang Yi Ke Da Xue Xue Bao, 2021 Apr 15; 41(3). PMID: 33849822    Free PMC article.
MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer.
Lei Sun, Man Li, +4 authors, Linlang Guo.
Front Pharmacol, 2021 May 01; 12. PMID: 33927616    Free PMC article.
Cancer neoantigens as potential targets for immunotherapy.
Weijie Ma, Brian Pham, Tianhong Li.
Clin Exp Metastasis, 2021 May 06; 39(1). PMID: 33950415    Free PMC article.
Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function.
John E Mullinax, MacLean Hall, +12 authors, Shari Pilon-Thomas.
J Immunother, 2021 Jan 15; 44(2). PMID: 33443972    Free PMC article.
Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review.
Tao Ouyang, Yanyan Cao, +7 authors, Chuansheng Zheng.
Front Oncol, 2021 May 29; 11. PMID: 34046338    Free PMC article.
Systematic Review.
Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study.
Koji Iinuma, Koji Kameyama, +12 authors, Takuya Koie.
Curr Oncol, 2021 May 01; 28(2). PMID: 33916792    Free PMC article.
Immunotherapy in non-small cell lung cancer: Update and new insights.
Xabier Mielgo-Rubio, Eider Azkona Uribelarrea, Laura Quintanta Cortés, María Sereno Moyano.
J Clin Transl Res, 2021 Jun 10; 7(1). PMID: 34104805    Free PMC article.
Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.
Qin Zhang, Liansha Tang, +2 authors, Weimin Li.
Front Immunol, 2021 Jun 15; 12. PMID: 34122422    Free PMC article.
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.
Michael J Grant, Roy S Herbst, Sarah B Goldberg.
Nat Rev Clin Oncol, 2021 Jun 26; 18(10). PMID: 34168333
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Scott N Gettinger, Mary W Redman, +16 authors, Roy S Herbst.
JAMA Oncol, 2021 Jul 16; 7(9). PMID: 34264316    Free PMC article.
Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy.
Si-Yuan Zhang, Xian-Yue Ren, +9 authors, Tong Wu.
Front Oncol, 2021 Jul 20; 11. PMID: 34277389    Free PMC article.
Emerging and multifaceted role of neutrophils in lung cancer.
Christian Aloe, Hao Wang, +3 authors, Steven Bozinovski.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295679    Free PMC article.
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.
Giorgia Guaitoli, Marcello Tiseo, +2 authors, Francesco Facchinetti.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295687    Free PMC article.
Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC).
Li-Chung Chiu, Shu-Min Lin, +3 authors, Ping-Chih Hsu.
Vaccines (Basel), 2021 Jul 03; 9(7). PMID: 34201650    Free PMC article.
Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions.
Ranjan Pathak, Arya Amini, +2 authors, Ravi Salgia.
Cancers (Basel), 2021 Jul 25; 13(14). PMID: 34298620    Free PMC article.
Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis.
Huihui Jiang, Aiqun Xu, +6 authors, Ran Wang.
Cancer Cell Int, 2021 Aug 16; 21(1). PMID: 34391428    Free PMC article.
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines).
Andrea De Giglio, Alessandro Di Federico, +2 authors, Francesco Gelsomino.
Curr Oncol Rep, 2021 Aug 29; 23(11). PMID: 34453261    Free PMC article.
Failure of Immunotherapy-The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer.
Justyna Błach, Kamila Wojas-Krawczyk, Marcin Nicoś, Paweł Krawczyk.
Int J Mol Sci, 2021 Aug 28; 22(16). PMID: 34445735    Free PMC article.
Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges.
Chu-Ling Li, Yong Song.
Chin Med J (Engl), 2021 Aug 04; 134(16). PMID: 34343148    Free PMC article.
PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC.
Kensuke Kojima, Tetsuki Sakamoto, +3 authors, Shinji Atagi.
Sci Rep, 2021 Sep 03; 11(1). PMID: 34471191    Free PMC article.
Prognostic Analysis of Lung Adenocarcinoma Based on DNA Methylation Regulatory Factor Clustering.
Yang Chen, Caiming Zhong, +2 authors, Hao Tang.
J Oncol, 2021 Sep 07; 2021. PMID: 34484331    Free PMC article.
Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy.
Olga Rodak, Manuel David Peris-Díaz, +2 authors, Piotr Dzięgiel.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572931    Free PMC article.
Immune checkpoints and immunotherapy in non-small cell lung cancer: Novel study progression, challenges and solutions.
Lin-Rui Ma, Jia-Xin Li, +5 authors, Pei-Yu Yan.
Oncol Lett, 2021 Oct 02; 22(5). PMID: 34594428    Free PMC article.
Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC.
Jing Chen, Yaser Alduais, Baoan Chen.
Cell Transplant, 2021 Oct 05; 30. PMID: 34606729    Free PMC article.
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
M Reck, T-E Ciuleanu, +24 authors, T John.
ESMO Open, 2021 Oct 05; 6(5). PMID: 34607285    Free PMC article.
Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy.
Wenxiang Zhang, Xiangyi Kong, +6 authors, Jing Wang.
Front Oncol, 2021 Oct 12; 11. PMID: 34631507    Free PMC article.
Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade.
Tian Tian, Zhaoming Li.
Front Oncol, 2021 Oct 12; 11. PMID: 34631560    Free PMC article.
Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer.
Michael Burke, Sawsan Rashdan.
Front Oncol, 2021 Oct 19; 11. PMID: 34660286    Free PMC article.
Immunotherapeutic Advances for NSCLC.
Marco Massafra, Maria Ilenia Passalacqua, +6 authors, Mariacarmela Santarpia.
Biologics, 2021 Oct 23; 15. PMID: 34675481    Free PMC article.
Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer.
Bin Wang, Hanfei Guo, +3 authors, Gang Zhao.
Cells, 2021 Oct 24; 10(10). PMID: 34685600    Free PMC article.
Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies.
Wenwen Yang, Caining Lei, +5 authors, Tiankang Guo.
Cancer Cell Int, 2021 Nov 04; 21(1). PMID: 34727927    Free PMC article.
Validation of a claims-based algorithm for identifying non-infectious pneumonitis in patients diagnosed with lung cancer.
Shane S Neibart, Daniella E Portal, +3 authors, Brian L Strom.
Pharmacoepidemiol Drug Saf, 2021 Aug 12; 30(12). PMID: 34378828    Free PMC article.
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort.
Sandip Pravin Patel, Edward Mayerson, +12 authors, Razelle Kurzrock.
Cancer, 2021 Apr 22; 127(17). PMID: 33882143    Free PMC article.
Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non-Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study.
Muhammad Khan, Zhihong Zhao, Xianming Li, Guixiang Liao.
Int J Gen Med, 2021 Dec 04; 14. PMID: 34858054    Free PMC article.
Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer.
Nathaniel Wiest, Umair Majeed, +3 authors, Rami Manochakian.
Front Oncol, 2021 Dec 07; 11. PMID: 34868953    Free PMC article.
Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer.
René J Boosman, Jacobus A Burgers, +5 authors, Rob Ter Heine.
Drugs, 2021 Dec 12; 82(1). PMID: 34894338
The foundations of immune checkpoint blockade and the ipilimumab approval decennial.
Alan J Korman, Sarah C Garrett-Thomson, Nils Lonberg.
Nat Rev Drug Discov, 2021 Dec 24;. PMID: 34937915
Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.
Yuan Cheng, Tao Zhang, Qing Xu.
MedComm (2020), 2022 Jan 04; 2(4). PMID: 34977873    Free PMC article.
The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.
Lin Ma, Bowen Diao, +3 authors, Xiangjiao Meng.
Cancer Commun (Lond), 2021 Oct 27; 41(12). PMID: 34699691    Free PMC article.
Recent advances in systemic therapy for hepatocellular carcinoma.
Huajun Zhang, Wuyang Zhang, Longying Jiang, Yongheng Chen.
Biomark Res, 2022 Jan 11; 10(1). PMID: 35000616    Free PMC article.
New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer.
Lucy Corke, Adrian Sacher.
Curr Oncol, 2022 Jan 21; 29(1). PMID: 35049678    Free PMC article.
Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer.
María Sereno, Oliver Higuera, +4 authors, Felipe Couñago.
World J Clin Oncol, 2022 Jan 25; 12(12). PMID: 35070737    Free PMC article.
Geographic heterogeneity in the outcomes of patients receiving immune checkpoint inhibitors for advanced solid tumors: a meta-analysis.
Manyu Li, Jiannan Yao, +2 authors, Guangyu An.
Transl Cancer Res, 2022 Feb 05; 10(1). PMID: 35116262    Free PMC article.
The incidence of gastrointestinal adverse events in patients with advanced non-small cell lung cancer (NSCLC) treated with PD-1 inhibitors: a meta-analysis.
Geng-Wei Huo, Fu-Yi Zhu, +6 authors, Peng Chen.
Transl Cancer Res, 2022 Feb 05; 10(7). PMID: 35116644    Free PMC article.
Proteomics score: a potential biomarker for the prediction of prognosis in non-small cell lung cancer.
Jie Peng, Jing Zhang, Dan Zou, Wuxing Gong.
Transl Cancer Res, 2019 Sep 01; 8(5). PMID: 35116940    Free PMC article.
Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort.
Matthew K Smith, Yin Chan, +7 authors, Christopher Ma.
J Can Assoc Gastroenterol, 2022 Feb 05; 5(1). PMID: 35118226    Free PMC article.
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer.
Baolin Liu, Xueda Hu, +8 authors, Zemin Zhang.
Nat Cancer, 2022 Feb 06; 3(1). PMID: 35121991
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Tina Cascone, William N William, +50 authors, Boris Sepesi.
Nat Med, 2021 Feb 20; 27(3). PMID: 33603241    Free PMC article.
Prognostic Value and Correlation With Tumor Immune Infiltration of a Novel Metabolism-Related Gene Signature in Pancreatic Cancer.
Hui Chen, Fuqiang Zu, +8 authors, Xiaodong Tan.
Front Oncol, 2022 Feb 08; 11. PMID: 35127473    Free PMC article.
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects.
Shengjie Tang, Chao Qin, +7 authors, Haining Zhou.
Cells, 2022 Feb 16; 11(3). PMID: 35159131    Free PMC article.
Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Nan Zhang, Jinwei Zhang, +4 authors, Xiaoxu Yu.
Front Oncol, 2022 Mar 01; 12. PMID: 35223476    Free PMC article.
Systematic Review.
Emerging Biomarkers for Diagnosis, Prevention and Treatment of Brain Metastases-From Biology to Clinical Utility.
Priyakshi Kalita-de Croft, Vaibhavi Joshi, Jodi M Saunus, Sunil R Lakhani.
Diseases, 2022 Mar 01; 10(1). PMID: 35225863    Free PMC article.
The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment.
Haoyue Hu, Yue Chen, +5 authors, Jun He.
Front Immunol, 2022 Mar 15; 13. PMID: 35281003    Free PMC article.
[Dual Immunotherapy in Advanced Non-small Cell Lung Cancer: 
the Progress and Clinical Application].
Haiyi Deng, Liqiang Wang, +2 authors, Chengzhi Zhou.
Zhongguo Fei Ai Za Zhi, 2022 Mar 01; 25(2). PMID: 35224963    Free PMC article.
Durvalumab as Consolidation Therapy in Post-Multimodal Interventional Treatment for Patients with Advanced Solid Tumors: A Preliminary Study.
Yuanming Li, Runqi Guo.
J Oncol, 2022 Mar 29; 2022. PMID: 35342409    Free PMC article.
Natural Product Alantolactone Targeting AKR1C1 Suppresses Cell Proliferation and Metastasis in Non-Small-Cell Lung Cancer.
Zhiwen Fu, Shijun Li, +5 authors, Chen Shi.
Front Pharmacol, 2022 Apr 05; 13. PMID: 35370661    Free PMC article.
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Adel Naimi, Rebar N Mohammed, +11 authors, Ehsan Razeghian.
Cell Commun Signal, 2022 Apr 09; 20(1). PMID: 35392976    Free PMC article.
CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma.
Zhou Li, Yanqi Feng, +3 authors, Shu Xia.
Int J Gen Med, 2022 Apr 15; 15. PMID: 35418778    Free PMC article.
[Research Progress of Immunotherapy for Non-small Cell Lung Cancer 
with Drive Gene Mutation].
Renfang Deng, Yue Zeng, +2 authors, Fang Wu.
Zhongguo Fei Ai Za Zhi, 2022 Mar 28; 25(3). PMID: 35340163    Free PMC article.
Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)-Their Incidence, Management, Multiorgan irAEs, and Rechallenge.
Raju Vaddepally, Rajiv Doddamani, +6 authors, Abhinav B Chandra.
Biomedicines, 2022 Apr 24; 10(4). PMID: 35453540    Free PMC article.
Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features.
Gengwei Huo, Wenjie Liu, Peng Chen.
Front Immunol, 2022 Apr 29; 13. PMID: 35479081    Free PMC article.
A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors.
Justin B Hackett, James E Glassbrook, +7 authors, Heather M Gibson.
Oncoimmunology, 2022 Apr 29; 11(1). PMID: 35481286    Free PMC article.
Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases.
Thomas Pierret, Niccolò Giaj-Levra, +3 authors, Elisa Gobbini.
Front Oncol, 2022 May 03; 12. PMID: 35494085    Free PMC article.
Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report.
Marie-Hélène Denault, Shelley Kuang, +8 authors, Cheryl Ho.
JTO Clin Res Rep, 2022 May 03; 3(5). PMID: 35498385    Free PMC article.
Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature.
Sara Baglivo, Martina Mandarano, +8 authors, Giulio Metro.
Oncol Ther, 2022 Jan 24; 10(1). PMID: 35066813    Free PMC article.
Decoding cancer's camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade.
Maria L Lotsberg, Austin Rayford, +6 authors, Agnete S T Engelsen.
Cancer Drug Resist, 2020 Oct 12; 3(4). PMID: 35582229    Free PMC article.